Introduction
Ovarian carcinomas (OCas) are the most common malignancy of the female reproductive system and the fourth leading cause of cancer deaths among women in Western countries (Luce et al., 2003) . Epithelial OCas, which arise from the ovarian surface epithelium (OSE), account for nearly 90% of all ovarian malignancies (Bell, 1991; Scully, 1995) . Epidemiological data strongly implicate ovarian steroids, particularly estrogens and progesterone (P4), as playing important roles in the pathogenesis of epithelial OCas (Risch, 1998; Rodriguez et al., 2002; Ho, 2003) . Pregnancy and oral contraceptive usage reduce, while estrogen replacement therapy (ERT) increases, risk of epithelial OCa (Risch, 1998) . However, ERT formulations with continuously added progestins do not raise OCa risk (Riman et al., 2002) , supporting the hypothesis that progestins may counteract the tumorigenic action of estrogens in human OSE (Ho, 2003) .
Progestins themselves or responses to progestins have been suggested as protective factors against epithelial OCa (Rao and Slotman, 1991; Rodriguez et al., 2002; Ho, 2003) . Lower plasma levels of progesterone (P4) correlate with higher OCa incidence (Modan et al., 1998) . At the cellular level, loss of tissue responsiveness to progestins elevates OCa risk (Gabra et al., 1995 (Gabra et al., , 1996 Davis et al., 1996; Lindgren et al., 2004) . Expression in general of progesterone receptor (PR), particularly the B-isoform, is associated with longer progression-free survival and is an independent predictor of more favorable outcome in OCa patients (Hempling et al., 1998; Akahira et al., 2000; Munstedt et al., 2000; Hornung et al., 2004) . These findings suggest that P4 and PR are likely involved in the development and progression of this disease, but the mechanisms have yet to be fully characterized. Several in vitro studies have demonstrated that P4 inhibits OCa cell growth (Bu et al., 1997; Hu and Deng, 2000; Syed et al., 2001; Yu et al., 2001) . Recently, in both normal OSE and OCa cell cultures, Syed and Ho (2003) demonstrated P4-induced apoptosis via an extrinsic apoptosis-initiation pathway involving activation of caspase-8 rather than the intrinsic, mitochondrion-related caspase-9 pathway. Rodriguez et al. (1998) in a 3-year trial, randomly assigned primates to receive an estrogen (ethinyl estradiol), a progestin (levonorgestrel), or the oral contraceptive Triphasil, which contains both hormones. Monkeys treated with progestin alone showed a four-to six-fold increase in apoptotic cells in their OSE when compared to untreated animals. Monkeys treated with the combined progestin plus estrogen regimen (Triphasil) exhibited a three-fold increase in apoptotic cells in their OSE, but those receiving estrogen treatment showed no increases. Taken together, these in vitro and in vivo findings support the proposition that progestin-induced apoptosis in OSE is functionally involved in the prevention of epithelial OCa development (Ho, 2003; Syed and Ho, 2003) .
The physiologic effects of progestins depend on activation of the PR, a member of the steroid-receptor superfamily of nuclear receptors (Lydon et al., 1995) . PR exists in two isoforms, produced by a single gene, with two different promoter and translational start sites. PR-B is the full-length receptor, while PR-A is missing the first 164 amino acids (Sartorius et al., 1994; Wen et al., 1994) . The PR protein consists of an aminoterminal domain capable of ligand-independent activation; a DNA-binding domain and hinge region in the central part of the protein; and a carboxy-terminal, ligand-binding domain with a secondary activation function that is ligand-dependent (Mangelsdorf et al., 1995) . Both PR-A and PR-B function as ligandactivated transcription factors, but several in vitro studies have demonstrated functional differences between the isoforms (Graham and Clarke, 2002; SmidKoopman et al., 2003) . Transcriptional activation by PR-B of the promoters that contain the progesteroneresponse element is more marked than that by PR-A, although the differences are cell-specific (Wen et al., 1994; Giangrande et al., 1997) . In addition, PR-A can also act as a transcriptional inhibitor of other steroid hormone receptors, including ER and PR-B (Kraus et al., 1995; Giangrande et al., 1997) .
It is known that steroid receptors constantly shuttle between the cytoplasm and the cell nucleus (GuiochonMantel et al., 1991 (GuiochonMantel et al., , 1994 (GuiochonMantel et al., , 1996 . Unliganded steroid receptors were originally thought to reside in the cytoplasm, but later studies indicated their primary residency in the nucleus (Welshons et al., 1984) . The presence of nuclear localization signals (NLSs) in steroid receptors mediates nuclear entry (Guiochon-Mantel et al., 1996) . Though the mechanism responsible for efflux to the cytoplasm remains poorly understood, the process requires ATP (Tang and DeFranco, 1996) and may involve nuclear export signals (NESs) (Saporita et al., 2003) . In breast (King and Greene, 1984; Lim et al., 1999) and endometrial (Leslie et al., 2005) cell studies, unliganded PR-As were found principally in the nucleus, whereas a significant fraction of PR-Bs was found in the cytoplasm. We still have no analogous information on cytoplasmic-nuclear distribution of liganded or unliganded PRs in normal and malignant OSE cells.
Although unopposed growth stimulation by estrogen has been proposed as a risk factor for epithelial OCa development (Taube et al., 2002) , the mode of action of estrogen in OSE tumorigenesis remains unknown. One of the biological functions of P4 or progestins in human OSE (HOSE) is to check cell proliferation by induction of apoptosis (Syed et al., 2001; Syed and Ho, 2003) . Hence, the status of PR expression in such a cellular environment may be an important determinant of cancer risk. Li et al. (2003) have recently reported upregulation of PR-B but not PR-A protein in primary OCa cultures when compared to normal OSE cultures.
In an OCa xenograft model, estrogens have been shown to regulate PR expression (Langdon et al., 1998) . In breast cells and other tissues/cells related to reproduction, estrogens are known to stimulate PR expression (Vienonen et al., 2002) . Nevertheless, we still know very little about how estrogens regulate PR or PR isoforms in HOSE or OCa cells, a serious concern to women using hormonal therapies pre-and postmenopausally. In this parallel study of two HOSE and two OCa cell lines, we identified three primary goals: (1) to compare the mode of action of estradiol-17b (E2) and its metabolite estrone (E1) in the regulation of PR-A and PR-B expression in the treated cells; (2) to ascertain whether intracellular distribution of PRs in normal OSE cells is different from that in their malignant counterparts by green fluorescence protein (GFP) tagging; and (3) to determine whether blockade of estrogen action enhances P4-induced apoptosis in OCa cell cultures. We hope the last of these goals provides preclinical data for a new combinational therapy involving an antiestrogen and a progestin.
All experiments were conducted in parallel with the use of the breast cancer cell line MCF-7 as a control in order to demonstrate cell type-specificity. Our data show direct inhibition of PR expression by estrogens in HOSE and OCa cell lines, which may be a key mechanism mediating estrogen tumorigenicity in human OSE.
Results

Expression of PR-A and PR-B in HOSE and OVCA cell lines
The protein expression levels of PR-A and PR-B were studied in two HOSE HOSE 642) and two OVCA (OVCA 429, OVCA 432) cell lines and a breast cancer cell line (MCF-7) by Western blot analyses (Figure 1 ), using a mouse anti-human PR antibody that recognizes both human PR isoforms PR-A (85-94 kDa) and PR-B (116-120 kDa). Both isoforms were apparently present at higher levels in OVCA cell lines than in HOSE cell lines (Figure 1 ). In MCF-7 cell lines, both PR-A and PR-B were expressed. The anti-human PR antibody recognized the PR-B as a doublet and PR-A as a single band in OSE cell lines; the doublet PR-B was particularly obvious in the OVCA cell lines. In the breast cancer cell line, the antibody recognized PR-A as doublet but PR-B as a single band.
PR expression was downregulated by E1 or E2 in HOSE and OVCA cell lines but upregulated by the estrogens in MCF-7
We studied the effects of estrogens (E1 and E2) on PR mRNA and protein expression in the same normal and ovarian cancer (OCa) cell lines. HOSE and OVCA cells were exposed to vehicle, E1 (10 À8 M), or E2 (10 À8 M) for 72 h with or without ICI 182,780 (ICI, 10 À5 M). As a positive control, MCF-7 cells were treated in a similar manner. Semiquantitative RT-PCR was used to quantify the levels of PR-AB and PR-B mRNA expression. We observed a marked decrease in the expression of PR-AB and PR-B mRNA in both HOSE and OVCA cell lines (Figure 2A, B) . Unlike the ovarian cell lines, the breast cancer cell line MCF-7 showed a significant elevation of PR-AB and PR-B mRNA expression following E1 or E2 treatment (Figure 2A, B) . However, E1 and E2 failed to downregulate the expression of PR-AB and PR-B in HOSE and OVCA cell cultures cotreated with ICI (10 À5 M). ICI alone had no effect on the expression of PR-AB and PR-B transcripts in HOSE and OVCA cells (Figure 2A, B) . In MCF-7 cell cultures, E1 or E2 upregulated the levels of PR-AB and PR-B mRNA, and their effects were blocked by ICI ( Figure  2A , B). Levels of PR-A and PR-B protein were assessed by Western blot in untreated and treated HOSE, OVCA, and MCF-7 cell lines ( Figure 2C ). Exposure to either estrogen significantly downregulated PR-A and PR-B protein in HOSE and OVCA cell lines ( Figure 2C , left panels a and b). Co-treatment of HOSE and OVCA cells with ICI effectively abolished the estrogenmediated loss of PR-A and PR-B expression. Treatment with ICI alone had no effect on PR expression in HOSE and OVCA cells. In sharp contrast to the effects on OSE cells, exposure of MCF-7 cells to E1 or E2 induced a marked elevation of PR-A and PR-B protein expression that was completely blocked by cotreatment with ICI ( Figure 2C , right panels a and b). Interestingly, treatment of MCF-7 cells with ICI alone inhibited the basal levels of PR-A and PR-B protein expression, a result likely caused by the blockade of PR upregulation by estrogens produced by the breast cancer cells.
Blockade of E1-E2 interconversion had no impact on estrogen-regulated PR expression in HOSE, OVCA, or MCF-7 cells
In cellulo there is a rapid interconversion of E1-E2 and visa versa by the enzymes type 1-and type 2-17b hydroxysteroid dehydrogenase (17b HSD, Tremblay and Poirier, 1998; Poirier et al., 2001) . To determine which estrogen is directly suppressing PR expression (rather than through conversion to its metabolic counterpart), we treated the HOSE, OVCA, and breast cancer MCF-7 cells with E1 or E2 (10 À8 M) in the presence or absence of EM251 (1 mM) (16a-Bromopropyl-estradiol) and EM416 (1 mM) (17-spiro-g lactone-estradiol), which are inhibitors of the enzyme 17b HSD type 1 and type 2, respectively. As demonstrated above, PR-A and PR-B protein expression was markedly reduced in HOSE and OVCA cells following treatment with E1 or E2 (Figure 3 , left and middle panels a and b), while their levels were dramatically elevated in MCF-7 cell cultures following exposure to either estrogen (Figure 3 , right panels a and b). Cotreatment of HOSE, OVCA, or MCF-7 cells with an estrogen and the 17b HSD inhibitors did not alter the levels or the direction of change of PR expression in the treated cells. The inhibitors per se had no effect on PR expression in HOSE or OVCA cells. However, they did stimulate PR-A and PR-B protein expression in MCF-7 cells, consistent with their reported weak estrogenic activities in some cell types (Tremblay and Poirier, 1998; Poirier et al., 2001) .
Estrogen-induced downregulation of PR protein expression in HOSE and OVCA cells was blocked by co-treatment with actinomycin D but not with cycloheximide
To determine whether the estrogen-induced downregulation of PR occurs at the level of transcription or translation, HOSE 12-12 and OVCA 429 cell cultures were treated with E2 (10 À8 M) in the presence of actinomycin D (2 mg/ml) or cycloheximide (10 mg/ml) for 72 h before levels of PR proteins were assessed by Western blot. As expected, E2 downregulated the expression of PR-A and PR-B protein in these cell lines (Figure 4a, b) . Co-treatment of E2-challenged HOSE or OVCA cell cultures with actinomycin D (2 mg/ml) Whole-cell extract of each sample containing equal amount of protein (100 mg) was separated by electrophoresis, and immunoblots were probed with 3 mg/ml of a mouse monoclonal anti-human PR antibody from DAKO Corporation at 41C. Representative blot is shown. PR-A and PR-B isoforms are labeled with an arrow. bActin was used as a loading control Figure 5a ) and increases in caspase-3 activity ( Figure 5b ) when compared to vehicle-treated cultures. The proapoptotic effect of P4 was blocked by cotreatment of OVCA cell cultures with RU486 (10 À5 M), though the antiprogestin alone had no effect on cell growth or apoptosis. A further decrease in cell growth and an additional increase in caspase-3 activity were observed when OCa cells were co-treated with P4 (10 À6 M) and ICI (10 À5 M), indicating synergistic effects between the two hormones. Cell growth/apoptosis in OVCA cell cultures were not affected by exposure to ICI alone (Figure 5a, b) .
In contrast to our observations in OCa cell lines, MCF-7 cell cultures showed a marked increase in cell growth but no change in caspase-3 activity in response to either the low (data not shown) or high dose of P4 (Figure 5a , b). Co-treatment of P4-treated MCF-7 cell cultures with RU486 blocked the growth-promoting action of P4, and the antiprogestin itself induced apoptosis in the breast cancer cells. ICI induced marked growth inhibition and apoptosis in MCF-7 cell cultures and a combined P4-plus-ICI treatment produced an attenuated response, suggesting that P4 and ICI antagonize each other's action (Figure 5a , b).
Localization of PR-A and PR-B in HOSE and OVCA cells using green fluorescent protein chimeras
To determine the localization of PR-A and PR-B in HOSE and OVCA cells, we transfected HOSE (HOSE 642, 
Discussion
We know little about the role played by estrogens in PR regulation in normal or malignant OSE cells. Only one study (Langdon et al., 1998) has demonstrated enhancement of PR expression in OCa xenografts when the host was treated with E2. Data from correlative studies vary, with some finding a positive correlation between levels of ER-a and PR (Langdon et al., 1998; Saegusa and Okayasu, 2000; Taube et al., 2003) , while others fail to establish a link between expression levels of the two classes of receptors in primary OCas (Hempling et al., 1998; Munstedt et al., 2000; Fujimura et al., 2001) . The present study is the first to demonstrate unequivocally that estrogens inhibit PR expression in two HOSE and two OVCA cells. Parallel experiments conducted with MCF-7 cells confirmed upregulation of PR by estrogens. Both the inhibitory and the stimulatory actions of estrogen on PR expression were blocked by the ER antagonist ICI. Interestingly, E1, which is traditionally viewed as a weak estrogen, was found to be as potent as E2 in suppressing PR expression. The activity of the two estrogens was direct and not attributable to their metabolic counterparts, since the action persisted in the presence of specific 17b-HSD type 1 and type 2 inhibitors. Both PR-A and PR-B were expressed at higher levels in OVCA cell lines than in HOSE cell lines. Ectopically expressed GFP-PR-A or GFP-PR-B undergoes ligand-dependent 'translocation' from the cytosol to the nucleus when HOSE cells are exposed to P4. However, ectopic expression of these hybrid molecules in OCa cells always resulted in nuclear localization, even in the absence of a ligand. Confirming our previous observation (Syed et al., 2001; Syed and Ho, 2003) , P4 was found to be a potent inducer of apoptosis for OVCA cells. Yet, it acted as a mitogen in MCF-7 cells. It has been widely established that estrogens induce PR expression not only in female reproductive tissues but also in normal and malignant mammary epithelial cells (Kontula et al., 1975; Nardulli et al., 1988; Wei et al., 1988) . In sharp contrast, the present study revealed significantly decreased PR-A and PR-B expression in HOSE or OVCA cell lines following exposure to an estrogen. The inhibitory action of estrogen on PR expression was principally at the transcriptional level, since it was blocked by actinomycin D but not by cycloheximide. Furthermore, the action was cell typespecific, affecting only OSE-derived cells, since parallel experiments conducted with the MCF-7 breast cancer cell line clearly demonstrated induced expression of PR by estrogen. Both the stimulatory and the inhibitory actions of estrogen on PR expression could be blocked by ICI, thus implicating ER signaling in both processes. No prior evidence points to a cell-or tissue-specific dependency of PR regulation by estrogen. A single report, however, has suggested such a possibility, reporting differential expression of PR (presumably controlled by estrogen) between the luminal epithelium and the glandular epithelium/stroma of the mouse uterus (Tibbetts et al., 1998) .
Currently, no known mechanism(s) account for the apparent paradoxical action of estrogen on PR expression. Two discrete promoters in the human PR gene have been identified and are believed to mediate separately the expression of the two PR isoforms. Notably, neither of them contains a classical estrogen responsive element (ERE) (Misrahi et al., 1988; Kastner et al., 1990) . Recent experimental evidence suggests that Estrogen-induced loss of PR expression K Mukherjee et al interaction of the ER with a half ERE/Sp-1 site in the promoter region of PR-A is responsible for its transactivation, while tethering of ERs to two Sp1 sites in the PR-B promoter enhances transcription of PR-B (Petz and Nardulli, 2000; Petz et al., 2002; Schultz et al., 2003) . Both ER-a and ER-b have been implicated in the upregulation of PR expression in a cell type-specific and PR isoform-dependent manner. In the ER-a-knockout mouse, expression of both uterine PR-A and PR-B was reduced to 60% of normal levels, but estrogen treatment did not restore their expression under a presumably intact ER-b axis (Hewitt and Korach, 2000) . In HeLa, BT20, and Ishikawa cell lines, PR-B promoter activity was enhanced by ER-a, but not by ER-b, while in SK-BR-3 cells both ER subtypes repressed PR-B promoter activity (Flototto et al., 2004) . In osteoblasts, although both ER subtypes enhanced PR-B promoter activity, activation of the PR-A promoter clearly showed a preferential dependency on ER-a (Rickard et al., 2002) . We have detected significant levels of ER-a, ER-b, and PR mRNA in HOSE cell cultures but reduced expression of ER-a and PR mRNA in OVCA cell lines; ER-b mRNA levels were comparable among normal and malignant OSE cell lines (Lau et al., 1999) . We here observed reversal of estrogen-induced loss of PR expression in HOSE and OVCA cell lines when they were subjected to ICI co-treatment. Since ICI is an antagonist for both ER subtypes, these data indicate involvement of ER signaling but do not conclusively identify the ER subtype that mediates the action of the estrogens in OSE cells.
The two PRs are functionally distinct and exert differential biological actions in different tissues/cells (Richer et al., 2002; Sartorius et al., 2003; Hopp et al., 2004 ). An appropriate ratio of PR-A to PR-B expression is critical for normal responsiveness to P4. For example, transgenic mice overexpressing either PR-A or PR-B show aberrant mammary architecture (Shyamala et al., 1998 (Shyamala et al., , 2000 . Normal breast cells express approximately equal amounts of the two PR subtypes, while the ratio of the two receptors varies extensively in cancer cells and may influence tumor phenotype (Sartorius et al., 2003) . In breast cancer cell lines, PR-A has been shown to act as a trans-dominant repressor of PR-B-mediated transcription (Vegeto et al., 1993) . In this study, we observed more PR-B than PR-A in the two HOSE cell lines . Nearly equal amounts of PR-A and PR-B were expressed in OVCA 432, but OVCA 429 seemed to express significantly higher levels of PR-B than PR-A. In general, the OVCA cell lines appear to express more PR (in particular the B isoform) compared to HOSE cell lines. This finding is in agreement with data reported by Li et al. (2003) showing a two-fold increase in PR-B in 23 primary OCa cultures when compared to levels in 23 normal OSE cultures. In fact, several studies have found a positive correlation between PR expression and favorable OCa outcome (Hempling et al., 1998; Akahira et al., 2000; Munstedt et al., 2000; Hornung et al., 2004) . In one study (Akahira et al., 2000) , PR-B but not PR-A labeling index was found to be an independent prognostic factor for OCa. Our findings, taken together with previous results, strongly implicate a role for PR in impeding OCa development and progression. Immunoblotting of PRs in HOSE and OVCA cell lines showed a doublet for PR-B, whereas PR-A was a single band. In contrast, PR-A, but not PR-B, appeared to exist in two sizes in the MCF-7 cell line. It has been established that human PR is phosphorylated at multiple sites (Clemm et al., 2000; Knotts et al., 2001) and that closely migrating PR bands represent different phosphorylated PR species (Takimoto et al., 1996) . At least 14 sites of phosphorylation have been reported on PR-B (Knotts et al., 2001) , and at least four sites are shared by both PR subtypes (Clemm et al., 2000) . Based on these results, we postulate that phosphorylation is one mechanism underlying the doublets observed for PR-B in OSE cells and for PR-A in MCF-7 cells. Future experiments intended to demonstrate differential phosphorylation of PR subtypes between OSE and MCF-7 cells should shed light on the physiological relevance of PR phosphorylation in receptor function regulation.
Using GFP-PR chimeras, we here demonstrate that intracellular distribution of PRs is dependent on the malignant state of the OSE cells. Unliganded PR-A and PR-B chimeras are localized to the cytoplasm of HOSE cells but undergo nuclear 'translocation' upon P4 exposure. In contrast, transfected GFP-PR chimeras are consistently localized to the nuclei of OVCA cells in a ligand-independent manner. Lim et al. (1999) have demonstrated in two murine mammary tumor lines and two primate (Cos-1 and HeLa) cell lines that the unliganded PR-A is located primarily in the nucleus, whereas a significant fraction of PR-B is present in the cytoplasm. Both forms undergo complete nuclear translocation when activated with ligand. A similar pattern of intracellular distribution of the two PR subtypes has been reported for human breast cells (King and Greene, 1984) and endometrial (Leslie et al., 2005) tissues/cells. In this regard, the ligand-independent localization of GFP-PRs in the nuclei of OCa cells observed here suggests disruption of the PR shuttling mechanism(s) in malignant OSE cells. Shuttling of PRs between nucleus and cytoplasm has been shown to depend on a multitude of factors. NLS and NES sequences on the receptor control import and efflux activities (Tyagi et al., 1998; Lim et al., 1999; Smith et al., 2000; Elbi et al., 2004 ). An NLS has been identified between amino acids 638 and 642 of PR, and there is a putative NES in the N-terminal region of both PR receptor (amino acids 190-198 and 516-524) and in the ligand-binding domain (amino acids 681-689 and 816-824) of the PR. Genomic or epigenomic changes in NLSs/NESs of PR in OCa cells may result in their localization in the cell nuclei in the absence of ligand. The release of steroid receptors from the nuclear matrix and efflux into the cytoplasm are critically dependent on ATP availability (Tang and DeFranco, 1996) . It is conceivable that competing requirements for ATP in OVCA cells limits availability of ATP for PR efflux from the nuclei of OVCA cells. A variety of PR chaperones have been characterized (hsp90, hsp70, p23, p60) (Johnson et al., 1996; Passinen et al., 2001) , and their dysregulation would inevitably influence nuclear/cytoplasmic distribution of PR. Finally, phosphorylation of PR Ser294 by MAP kinase or CDK2 kinase has been shown to cause unliganded PR to reside in the nucleus . Investigations are in progress to identify and characterize the mechanism(s) responsible for nuclear localization of unliganded PRs in OVCA cells.
E1 has been characterized as an estrogen that binds to ERs with lower affinities than E2 (Dandliker et al., 1978; Kreitmann et al., 1979; Shafie and Brooks, 1979; Kuiper et al., 1997) . However, we found in a previous study that E1 and E2 were equally potent in stimulating HOSE and OVCA cell growth (Syed et al., 2001 ). Here we discovered that E1 was as effective as E2 in suppressing PR expression in HOSE/OVCA cells and in stimulating PR expression in MCF-7 cells. In glandular and extra- Estrogen-induced loss of PR expression K Mukherjee et al glandular tissues, E1 is rapidly converted to E2 by type I 17b-HSD and vice versa by type 2 17b-HSD. When we treated HOSE, OVCA, or MCF-7 cell cultures with E1 or E2 in the presence of specific inhibitors of type 1 and type 2 17b-HSDs (Tremblay and Poirier, 1998; Poirier et al., 2001) , we observed no changes in the cellular responses to the estrogen under examination. These findings indicate that the actions of the two estrogens are direct and not the result of conversion to their metabolic counterpart(s). Before menopause, E2 is the major circulating estrogen, produced primarily by the ovaries. After menopause, E1 becomes the predominant form of estrogen, derived from metabolic conversion from androstenedione at extraglandular sites (Vaughn et al., 1976) . Hence, our data strongly suggest that postmenopausal E1 synthesis could be a key factor in the genesis of epithelial OCa, since the steroid is highly effective in promoting cell growth and reducing cellular responsiveness to P4, which is now known to curb OCa cell growth.
The OCa and MCF-7 cell lines showed remarkable differences in their responses to P4 and ICI treatment, singularly or conjointly, with regard to cell growth and death. As we observe here, and has been observed before (Syed et al., 2001 ), P4 at a high dose (10 À6 M), but not a low dose (10 À9 M), causes apoptosis in OVCA cells. The action of P4 was blocked by cotreatment with RU486, demonstrating hormonal specificity. Interestingly, the antiprogestin per se exerted no effects on cell growth/ proliferation in OVCA cell cultures, a finding different from data reported by Wang et al. (2004) that demonstrated induction of cell death by the antiprogestin in SKOV-3 OCa cell cultures. This discrepancy may be due to differences in the hormonal receptor statuses (Lau et al., 1999) among various OCa cell lines. Similarly, ICI per se, at 10 À5 M, had no apoptotic effect on OVCA cells. Intriguingly, combined treatment with P4 and ICI induced synergistic cell-kill effects on OVCA cells. One plausible explanation for the synergism between ICI and P4 is the likelihood that ICI, via its action as an ER-antagonist, blocks endogenous estrogen-induced suppression of P4 expression. In this manner, it maintains PR expression in OVCA cells and allows for more effective P4 action, which in the case of OVCA cells is induction of apoptosis. Indeed, ICI plus P4 cotreatment induced more cell loss and higher caspase 3 activity in OVCA cells than P4 alone. Clinically, it has been reported that epithelial OCas produce estrogens (Heinonen et al., 1982; Taube et al., 2002) , although we have not established whether estrogens are produced by the OVCA cell lines. On the contrary, P4 promoted cell growth and ICI induced apoptosis in MCF-7 cell cultures. The proapoptotic activity of ICI in MCF-7 is clearly due to its suppression of ER, which is needed for breast cancer cell growth and survival (Key and Pike, 1988; Clarke et al., 2004) . Our observations in MCF-7 cells are consistent with previous findings.
A formulation based on the combined action of P4 and ICI may have good therapeutic efficacy for the treatment and prevention of certain OCas. However, based on our data, by combining a progestin with ICI, the potent proapoptotic action of the antiestrogen should negate the mitogenic action of the progestin and induce an overall cell-kill effect on breast cancer cells. Thus, such a combinational treatment therapy may be effective for the prevention/treatment of both ovarian and breast cancer in specific populations of women. Finally, with regard to the risk of HRT usage after menopause, inclusion of a progestin in ERT formulations is apparently beneficial for OCa prevention, but it may increase risk of breast cancer, an issue that remains to be investigated further. 
Materials and methods
Chemicals and reagents
Cell cultures and cell lines
The origin and culture conditions of the two HOSE and two OVCA cell lines have been previously described (Syed et al., 2001 (Syed et al., , 2002 . In short, HOSE 642 and HOSE 12-12 were derived from normal OSE obtained from a 46-year-old normal individual and a 39-year-old patient with ovarian stromal hyperplasia, respectively. After immortalization, the primary cultures had a normal epithelial cell phenotype, that is, a cobble-stoned appearance in cell culture, epithelial cytokeratin staining, responsiveness to transforming growth factor-binduced growth arrest, no detectable CA125 production, and a lack of in vivo tumorigenicity (Tsao et al., 1995) . The two OVCA cell lines, OVCA 429 and OVCA 432, were derived from patients with late-stage serous OCas, as described elsewhere (Bast et al., 1981) . These cell lines were cultured in a 1 : 1 mixture of Medium 199/MCDB 105 supplemented with 10% heat-inactivated (HI)-FBS, penicillin (100 U/ml), and streptomycin (100 mg/ml). The human breast cancer cell line MCF-7 was obtained from American Type Culture Collection (Rockville, MD, USA). MCF-7 cells were cultured in DMEM/ F12 supplemented with 5% HI-FBS and antibiotics. All media were free of phenol red. Cell cultures were maintained at 371C in a humidified atmosphere of 5% CO 2 /95% air. ) and allowed to attach for 24 h. In experiments in which the effects of hormones were studied, cells were cultured in a medium supplemented with 10% charcoalstripped HI-FBS for 48 h prior to hormone treatment. To study the direct effects of E1 and E2, cell cultures were treated daily for 3 days with one of the estrogens at 10 À8 M in the absence or presence of 1 mM of EM251 (type 1 17b-HSD inhibitor) and EM416 (type 2 17b-HSD inhibitor). The concentrations chosen for these blockers were based on previous reports of efficacy in blocking metabolic conversion while eliciting no estrogenicity (Tremblay and Poirier, 1998; Poirier et al., 2001) . To demonstrate that estrogenicity was mediated via ER signaling, some estrogen-treated cultures were cotreated with ICI, an antagonist for ER-a and ER-b, at a final concentration of 10 À5 M. Actinomycin D (2 mg/ml) or cycloheximide (10 mg/ml) were added to some estrogen-treated cultures to inhibit transcription or translation, respectively. In experiments examining the effects of P4 and ICI, low (10
and high (10 À6 M) concentrations of P4 were used. We previously reported low concentrations of P4 (10
either exert no effects or slight growth promoting effects on HOSE/OVCA cell lines whereas higher concentrations (10 À8 -10 À6 M) of P4 consistently induce cell death in these cell lines (Syed et al., 2001; Syed and Ho, 2003) . The higher concentrations of P4 used in our cell culture experiments could be achieved during the luteal phase of the female cycle as well as during pregnancy. In premenopausal women, serum P4 levels fluctuate in the range of 2-14 ng/ml or 0.6-4.7 10 À8 M (Ross et al., 1981) . The higher concentrations are only reached during the midluteal phase of the female cycle. Furthermore, a 10-fold increase in P4 to 10 À7 -10 À6 M range is noted during pregnancy (Simpson and MacDonald, 1981) .
The PR antagonist RU486 (10 À5 M) was used to demonstrate the specificity of P4 action in (1) the intracellular localization of GFP-PRs and (2) cell growth and apoptosis. The direct effects of the antiprogestin on cell growth/death in HOSE, OVCA, and MCF-7 cells were also investigated. To demonstrate synergistic or antagonistic effects between P4 and ICI, the antiestrogen at 10 À5 M was used to cotreat some P4-treated cultures. After treatment, cell cultures were subjected to cell growth or caspase 3 assays. Alternatively, cells were harvested for total RNA isolation or protein extraction.
RNA isolation and quantification of mRNA levels by semiquantitative RT-PCR Total RNA was isolated from cells with TRI-reagent (Sigma) according to the manufacturer's instructions and quantified by UV absorbance. The integrity of RNA was confirmed by criteria previously described (Syed et al., 2001 (Syed et al., , 2002 . Total RNA (1 mg) from each sample was reverse-transcribed using GeneAmp RNA PCR kit (Perkin Elmer, CT, USA). Complementary DNA (cDNA) obtained from a RNA sample was stored at À201C until use.
To investigate the relative expression levels of PR-AB, PR-B, and b-actin mRNA in each cell culture, semiquantitative RT-PCRs were performed. Primers for subsequent PCR were as follows: PR-AB, 5 0 sense-CCTCGGACACCTTGCCTGAA and 3 0 antisense-CGCCAACAGAGTGTCCAAGAC (1576-1794, 239 bp); specific PR-B primers were 5 0 sense-TAGT-GAGGGGGCAGTGGAAC and 3 0 antisense-AGGAGGGG GTTTCGGGAATA (955-1377, 442 bp); The primers for bactin were 5 0 sense-CCAACCGCGAGAAGATGAC and 3 0 antisense-GGAAGGAAGGCTGGAAGAGT (382-841, 459 bp). Aliquots (2 ml) of first-strand cDNA were subjected to PCR amplification. Hot start PCR using AmpliTaq Gold DNA polymerase (Perkin-Elmer) was used in all reactions to minimize nonspecific product amplification. The annealing temperature for all primers was 601C. The number of amplification cycles was 33 for PR-AB, 35 for PR-B, and 18 for b-actin. The other conditions were the same, with initial denaturation for 6 min at 941C, cycle denaturation for 1 min at 941C, annealing for 1 min, and extension at 721C for 1 min. The PCR products were fractionated on 2% agarose gel and quantified after ethidium bromide staining. The fluorescence images were visualized under ultraviolet transillumination, captured using a digital camera (Kodak, EDAS 290, Eastman Kodak, Rochester, NY, USA), converted into digitized signals, and intensities of each band quantified by the Kodak 10 Image analysis software version 3.5 (Eastman Kodak). Signal intensities of PR-AB and PR-B were normalized to those of b-actin to produce arbitrary units of relative message abundance. The reproducibility of the quantitative measurements was evaluated by three independent cDNA syntheses and PCR runs from each preparation of RNA. The means of the replicated measurements were calculated and shown as mean7s.d.
Immunoblot analysis
Cellular extracts were prepared using RIPA lysis buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS. To avoid degradation of proteins, a protease inhibitor cocktail III (Calbiochem, San Diego, CA, USA) was added at 2%. Total protein was quantified using a BCA protein assay kit (Pierce, Rockford, IL, USA). Extracted proteins (100 mg) from each cell culture were separated by electrophoresis on 7.5% SDS-polyacrylamide gels. The proteins were transferred onto PVDF membranes. To inhibit nonspecific binding, the membranes were blocked either in 5% BSA or 5% nonfat dry milk in PBS-0.1% Tween-20 (PBST) for 2 h before immunoblotting. The blots were incubated overnight at 41C in blocking solution with mouse anti-human PR antibody (PgR 1294, 3 mg/ml, Dako Corporation) at 3 mg/ml. After washing with PBST, the membranes were then incubated with the secondary antibody (anti-mouse Ig-HRP, Amersham, City and State) at 1 : 5000 dilution in 3% non-fat dry milk in PBST for 2 h at room temperature. After washing, bound antibodies were detected with Super Signal West Femto detection reagents visualized by radioautography. Anti-b-actin primary antibody (1 : 4000) was purchased from Sigma.
Cell proliferation assay
Cell growth was measured with the Cell Titer Aqueous Assay (Promega), which is based on conversion of MTS tetrazolium to a colored formazan product by viable cells. Cells were seeded at 1000 per well in 96-well plates; 24 h later the cultures were treated with different hormonal regimens. At the end of the treatment period, 400 ml of the MTS/MPS/medium solution was added to each well, and plates were incubated for 4 h in a humidified atmosphere. The amount of formazan formed during this period was measured as absorbance at 490 nm in a spectrophotometer. Cell growth in untreated control cultures was arbitrarily assigned a value of 1, and relative cell growth in a treated culture was expressed as foldchange over control untreated cultures. Data points are group mean values7s.d. from three separate experiments.
Caspase 3 activity assay
Cells were harvested by centrifugation at 400 g for 10 min at room temperature, washed once with PBS, and the cell pellets were lysed in 50 ml of ice-cold lysis buffer provided with the Apo Alert Caspase-3 Colorimetric Assay Kit (BD Biosciences Clontech). The cell lysates were microcentrifuged at maximum speed for 3 min at 41C, supernatants transferred to new tubes, and 50 ml of the supernatant was transferred to a reaction well in a 96-well plate. In total, 50 ml of 2 Â reaction buffer/DTT Mix and 5 ml of 1 mM caspase-3 substrate (DEVD-pNA; 50 mM final concentration) were then added to each reaction and incubated at 371C for 1 h. Absorbance was recorded on a plate reader at 405 nm. The net increase of absorbance indicated enzyme activity.
Fluorescence microscopy
Coverslips were coated with 0.5% gelatin and placed at the bottom of six-well plates. HOSE or OVCA cells were seeded at 0.5 Â 10 6 cells per well and cultured for 24 h before they were transfected with 1 mg of DNA obtained from GFP-PR-A or GFP-PR-B plasmids by the Lipofectaminet Reagent (Invitrogen) as per the manufacturer's instructions. At 24 h following transfection, medium was replaced with medium supplemented with charcoal-stripped HI-FBS and cells were treated with progesterone (10 À8 M) or its antagonist RU486 (10 À5 M).
Control cultures were treated with vehicle alone. After 4 h, cells on coverslips were rinsed carefully with ice-cold PBS and fixed with 3.7% formaldehyde in PBS for 10 min. The fixed cells were washed again with PBS and mounted on slides using the Slow-Fade antifade kit (Molecular Probes, Eugene, OR, USA). The slides were viewed by fluorescence microscopy using a standard fluorescein isothiocyanate filter set.
Statistical analyses
Statistical analysis was carried out using ANOVA, followed by Tukey's post hoc test. Values are presented as the mean7s.d. and are considered significant at Po0.05.
